Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, WAVE Life Sciences's Enterprise Value is €540.85 Mil.
WAVE Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-159.16 Mil. Therefore, WAVE Life Sciences's EV-to-FCF for today is -3.40.
The historical rank and industry rank for WAVE Life Sciences's EV-to-FCF or its related term are showing as below:
FRA:1U5'
s EV-to-FCF Range Over the Past 10 Years
Min: -72.84 Med: -5.15 Max: 0.1
Current: -3.33
During the past 13 years, the highest EV-to-FCF of WAVE Life Sciences was 0.10. The lowest was -72.84. And the median was -5.15.
FRA:1U5's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs FRA:1U5: -3.33
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WAVE Life Sciences (FRA:1U5) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
WAVE Life Sciences's PE Ratio (TTM) for today is calculated as:
WAVE Life Sciences's share price for today is €5.00.
WAVE Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.910.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
WAVE Life Sciences EV-to-FCF Related Terms
WAVE Life Sciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for WAVE Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, WAVE Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's EV-to-FCF falls into.
WAVE Life Sciences's current Enterprise Value is €540.85 Mil.
WAVE Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-159.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (FRA:1U5) has a EV-to-FCF of -3.40 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on WAVE Life Sciences and its competitors. According to the industry distribution chart, WAVE Life Sciences ranks #999999 out of 335 companies in the Biotechnology industry.
Is WAVE Life Sciences' EV-to-FCF too high?
WAVE Life Sciences' current EV-to-FCF is -3.40. Based on the distribution chart, WAVE Life Sciences ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' EV-to-FCF compare to CGEM and LXRX?
According to the Biotechnology industry distribution chart, WAVE Life Sciences ranks #999999 out of 335 companies for EV-to-FCF. This places WAVE Life Sciences in the lower half of its industry. The industry median EV-to-FCF is 15.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on WAVE Life Sciences and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WAVE Life Sciences's current EV-to-FCF is -3.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (FRA:1U5) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.66, compared to a current price of €5.00 — trading 36.6% above its estimated fair value. The current EV-to-FCF is -3.40. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For WAVE Life Sciences (FRA:1U5), the current EV-to-FCF is -3.40 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WAVE Life Sciences (FRA:1U5) Overvalued in 2026?
Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued.
The current stock price of €5.00 is trading 36.6% above its estimated GF Value™ of €3.66.
GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:1U5:
EV-to-FCF: -3.40
GF Value™: €3.66 vs. price of €5.00 (36.6% above fair value)
No single metric tells the full story. See the FRA:1U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score
Get the complete analysis for FRA:1U5
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1U5 has been successfully added to your 
